TELA TELA Bio

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference.

TELA’s management is scheduled to present at Piper Sandler’s 36th Annual Healthcare Conference at 12:00 pm ET on December 3rd, 2024. Interested parties can access the live and archived webcast at .

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit .

Investor Contact

Greg Chodaczek

347-620-7010



EN
19/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conf...

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 36th Annual Healthcare Conference at 12:00 pm ET on December 3rd, 2024. Interested parties can access the live and archived webcast at . About TELA ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

TELA Bio Reports Third Quarter 2024 Financial Results

TELA Bio Reports Third Quarter 2024 Financial Results Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) --  TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Reported revenue of $19.0 million in the third quarter, representing growth of 26% over the prior year pe...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 2, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted purs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch